Therapy Areas: Autoimmune
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
23 July 2024 - Swedish clinical-stage diabetes company Diamyd Medical (STO:DMYD-B) announced on Tuesday that it has received positive feedback from the US Food and Drug Administration (FDA) about an A...
Atara Biotherapeutics gains FDA Priority Review for tabelecleucel
17 July 2024 - T-cell immunotherapy company Atara Biotherapeutics Inc (Nasdaq: ATRA) announced on Wednesday that the U.S. FDA has accepted its Biologics License Application (BLA) for tabelecleucel (ta...
Kyverna's KYV-101 granted FDA Regenerative Medicine Advanced Therapy designation
16 July 2024 - Kyverna Therapeutics, Inc. (Kyverna) a California-based clinical-stage biopharmaceutical company, announced on Monday that the US Food and Drug Administration (FDA) has granted Regenera...
Lilly to acquire Morphic to enhance inflammatory bowel disease treatments
8 July 2024 - Medicine company Eli Lilly and Company (NYSE: LLY) and biopharmaceutical company Morphic Holding Inc (NASDAQ: MORF) on Monday announced a definitive agreement for Lilly to acquire Morphi...
BioSenic expands US patent portfolio for ATO use in sepsis treatment
5 July 2024 - Biotech company BioSenic (Euronext Brussels/Paris:BIOS) announced on Friday that it has filed a continuation patent application in the United States to protect the use of arsenic trioxid...
Q32 Bio added to Russell 3000 Index
2 July 2024 - Q32 Bio Inc. (Nasdaq: QTTB), a US-based clinical stage biotechnology company, announced on Monday that it is joining the Russell 3000 Index at the conclusion of the 2024 Russell Indexes ...